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SUMMARY
The purpose of the present study was to compare the susceptibility to four antifungal agents of 69 Cryptococcus neoformans
strains isolated from AIDS patients with that of 13 C. neoformans strains isolated from the environment. Based on the NCCLS M27-
A methodology the Minimal Inhibitory Concentrations (MICs) obtained for amphotericin B, itraconazole and ketoconazole were
very similar for clinical and environmental isolates. Clinical isolates were less susceptible to fluconazole than environmental isolates.
The significance of these findings and aspects concerning the importance, role and difficulties of C. neoformans susceptibility testing
are also discussed.
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INTRODUCTION
Cryptococcus neoformans is an opportunistic yeast recognized as
the etiological agent of human cryptococcosis. This widespread organism
was noted to occur in immunosuppressed hosts especially those with
AIDS, for whom disseminated disease is being increasingly reported25.
Cryptococcus neoformans is rarely isolated from healthy individuals
and does not appear to be a common human commensal. The sporadic
nature of human cryptococcosis, the extreme rarity of documented
human-to-human transmission events3,12 and the high prevalence of C.
neoformans in the environment indicate that human infection is acquired
from environmental sources5. It was assumed that inhalation of infectious
particles from avian excreta, the main natural source of environmental
strains of the var. neoformans, is the major route for human infection5 .
Based on the strong relationship between environmental and clinical
C. neoformans strains5 and the few comparative studies carried out on
antifungal susceptibilities9,10, the purpose of this study was to evaluate
the susceptibility of 82 C. neoformans strains isolated in the state of Rio
Grande do Sul, Brazil.
MATERIAL AND METHODS
Cryptococcus neoformans strains: a total of 82 strains were studied.
Forty-eight isolates were obtained from cerebrospinal fluid (43), blood
(3) and sputum (2) from 38 AIDS patients at the Hospital Universitário
de Santa Maria, Santa Maria (RS, Brazil) from January 1996 through
December 2000. Thirty-eight strains were obtained from patients during
the initial diagnosis of cryptococcal infection and ten strains were
obtained after the patients had been treated with amphotericin B or
fluconazole. Other twenty-one clinical samples were kindly provided
by Central Laboratory of Instituto de Pesquisas Biológicas da Secretaria
da Saúde e Meio Ambiente in Rio Grande do Sul State – LACEN
(fourteen) and by Hospital São Lucas (seven), from Porto Alegre.
Environmental samples (thirteen) were from pigeon excreta originated
from two different cities in the Rio Grande do Sul State, Porto Alegre
and Santa Cruz do Sul, located in the South region of Brazil and separated
apart by a distance of 150 km. For C. neoformans isolation, 1.0 g of
weathered pigeon excreta was added to 10 ml sterilized saline solution
with both chloramphenicol and ampicillin at 150 mg ml–1 each. After
filtration through sterilized gauze, aliquots of 10–1 and 10–2 dilutions
were inoculated onto birdseed agar plates and incubated at 37 °C up to
21 days. All strains were identified as C. neoformans by a positive Niger
seed agar response, positive urease test, ability to grow at 37 °C and
negative nitrogen test. The profiles of carbon compound assimilation
were also determined5. Each isolate was identified as C. neoformans var
neoformans by the canavanine-glycine-bromothymol-blue-agar method
described by KWON-CHUNG et al.18.
Antifungal agents: the antifungal agents used were amphotericin B
(Sigma), itraconazole and ketoconazole (Jansen Pharmaceutica), and
fluconazole (Pfizer).
Susceptibility testing: we used the macrodilution technique19. RPMI
1640 medium (American Biorganics Inc.) containing L-glutamine was
prepared according to manufacturer instructions. After reconstitution
the medium was supplemented with glucose to obtain a final
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concentration of 2%, and buffered to pH 7.0 with 3-(N-
morpholino)propanesulfonic acid (MOPS; Sigma) to a final concentration
of 165 mM. The procedures of inoculum preparation and incubation
were those of the M27-A methodology19. The minimal inhibitory
concentration (MIC) of amphotericin B was defined as the lowest
concentration of drug which resulted in complete inhibition of visible
growth. The MICs of azoles were defined as the lowest concentration of
drug which resulted in an 80% reduction of fungal growth compared to
control. The assays were read 48 h after inoculation. The data are reported
as MIC ranges and MICs at which 50% and 90% of the isolates were
inhibited. Candida parapsilosis ATCC 22019 and Candida krusei ATCC
6258 were used as quality control for the susceptibility tests.
RESULTS
Table 1 summarizes the in vitro susceptibilities of 69 clinical and 13
environmental isolates.
Amphotericin B showed similar MIC ranges against the strains from
both sources but MIC 50% and MIC 90% were slightly more elevated
for the environmental strains.
Fluconazole showed a broad MIC range, varying from 0.125 to
16 g/ml for clinical and environmental isolates. The MICs 50% and
90% were more elevated for clinical than environmental isolates.
For itraconazole the MICs were within narrow ranges (0.031-
0.25 g/ml) for clinical and environmental isolates and the MIC 50%
was the same for all strains. The MIC 90% for clinical isolates was more
elevated than environmental isolates. Ketoconazole showed narrow MIC
ranges from 0.031 g/ml to 0.5 g/ml. The MIC 50% for clinical isolates
was more elevated than environmental isolates, but the MIC 90% was
similar for clinical and environmental strains.
DISCUSSION
The concern about C. neoformans susceptibility is not recent4;
however considering the newly standardized testing, the results currently
obtained are becoming more appreciated because they allow inter-
laboratory comparisons. Our purpose was to compare clinical and
environmental isolates because the emergence of resistance is an
apparently rare phenomenon that encompasses development after long
treatment with antifungals (secondary resistance) or primary resistance
without former exposure to these agents8,23.
Our results are closely similar to those reported by other
authors7,9,12,14,27 and seem to indicate susceptibility of C. neoformans
strains to antifungal agents. However, some aspects about susceptibility
tests deserve attention.
The narrow MIC ranges of amphotericin B have been pointed out to
be a consequence of RPMI 1640 medium which may not be a good
culture medium to warrant good C. neoformans growth and thus, could
be hindering the detection of resistance8,11,23 . Reports about amphotericin
B-resistant C. neoformans are scarce15,16,17,24 even during the AIDS era.
Based on the M27-A methodology, our MIC ranges obtained for
amphotericin B allow us to conclude that the clinical and environmental
isolates studied are susceptible to the drug, as also reported by others7,9,14.
Fluconazole has been shown to be an effective alternative to
amphotericin B in the treatment of cryptococcal meningitis and is the
most commonly used antifungal agent in maintenance therapy for this
disease25. The majority of cases of meningitis due to C. neoformans
resistant to fluconazole have been reported in AIDS patients after long
treatments or prophylaxis with fluconazole1,2,21,22. Furthermore, a
fluconazole resistant strain isolated from an immunocompetent patient
without exposure to this triazole has been reported, which alerts that
environmental strains can be primarily resistant to fluconazole20. So,
cryptococcal susceptibility to fluconazole could be an important predictor
of treatment success and MICs can be useful to monitor the possible
development of resistance during therapy and to identify primary
resistance8,28. Our results based on MIC 50% and MIC 90% show that
clinical isolates were less susceptible to fluconazole than environmental
isolates even though MIC  16 g/ml was observed in both groups of
strains. However, the overall susceptibility of the southern Brazilian C.
neoformans isolates to fluconazole was very similar to that reported for
American isolates and in another Brazilian study9,27,28. FRANZOT &
HAMDAN9 found that 100% of isolates from Minas Gerais (a central
Brazilian state) were inhibited by  16 g/ml of fluconazole, as also
observed in the present investigation.
C. neoformans is extremely susceptible to itraconazole in vitro26;
our data are similar to those reported by several other investigators who
used the same methodology7,9. It seems clear that C. neoformans
resistance to itraconazole is too rare and cross-resistance with fluconazole
does not occur1,6,21,22. However, IWATA et al.13 obtained an itraconazole–
resistant C. neoformans strain after exposure to N-nitro-nitrosoguanidine.
The mechanism of action of itraconazole which blocks the lanosterol
14 -demethylase and the NADPH-dependent-3-ketosteroid reductase
in C. neoformans may have implications both for its potent antifungal
activity and for its reduced development of cross-resistance compared
to other azoles5. We did not observe differences in itraconazole MICs
Table 1
In vitro susceptibility of C. neoformans strains to amphotericin B and azoles
Antifungal agents and MIC (µg/ml)a
strains groupb Range 50% 90%
Amphotericin B
Clinical 0.0625-0.5 0.125 0.25
Environmental 0.0625-0.5 0.25 0.5
Fluconazole
Clinical 0.125- 16 2.0 8.0
Environmental 0.125- 16 0.5 4.0
Itraconazole
Clinical 0.031-0.25 0.125 0.25
Environmental 0.031-0.25 0.125 0.125
Ketoconazole
Clinical 0.031-0.5 0.125 0.125
Environmental 0.031-0.25 0.0625 0.125
a
 50% and 90%, MICs at which 50 and 90% of the strains, were inhibited,
respectively; b Clinical isolates (n = 69); environmental isolates (n = 13).
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50% between clinical and environmental isolates and our results are
similar to those reported by others5,9.
Ketoconazole is not indicated for the treatment of cryptococcal
meningoencephalitis but was included in the present study in order to
evaluate a possible cross-resistance among azoles. The ketoconazole
MICs observed were as low as that obtained for itraconazole and the
interpretation is the same. The 3 C. neoformans strains that showed
fluconazole MICs = 16 g/ml did not demonstrate elevated MICs for
itraconazole and ketoconazole.
Finally, we found that clinical and environmental C. neoformans
strains showed a similar pattern of susceptibility to amphotericin B,
itraconazole and ketoconazole. The clinical isolates were less susceptible
to fluconazole than the environmental isolates, possibly as a consequence
of therapy with this agent. As postulated by others, during therapy of
cryptococcosis the susceptibility tests of recurrent isolates may monitor
the development of secundary resistance, because if susceptibility does
not predict successful therapy, resistance should often predict therapeutic
failure1,2,6,8,15,16,19,21,22,23,24,28.
RESUMO
Suscetibilidade in vitro a antifúngicos, de amostras clínicas e
ambientais de Cryptococcus neoformans isoladas no sul do Brasil
Comparou-se a suscetibilidade de 69 amostras de C. neoformans
isoladas de pacientes com SIDA com 13 amostras de C. neoformans
isoladas do meio ambiente, frente a quatro agentes antifúngicos. Com
base na metodologia preconizada pelo NCCLS (M27-A) as concentrações
inibitórias mínimas (CIMs) obtidas para a anfotericina B, itraconazol e
cetoconazol foram muito semelhantes nos dois grupos estudados.
Todavia, frente ao fluconazol, os isolados clínicos evidenciaram menor
sensibilidade do que os provenientes do meio ambiente. Alguns aspectos
envolvendo a importância e dificuldades dos testes de suscetibilidade
com Cryptococcus neoformans são também discutidos pelos autores.
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